Loading...

Felix Feng, MD

TitleAssociate Professor
SchoolUCSF School of Medicine
DepartmentRadiation Oncology
Address1450 Third St
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Selected Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2016 Dec 21. PMID: 28001303.
      View in: PubMed
    2. Tan M, Xu J, Siddiqui J, Feng F, Sun Y. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer. 2016 Dec 12; 15(1):81. PMID: 27955654.
      View in: PubMed
    3. Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int. 2016 Nov 14. PMID: 27844132.
      View in: PubMed
    4. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. PMID: 27743920.
      View in: PubMed
    5. Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep. 2016 Nov; 9:51-54. PMID: 27713863.
      View in: PubMed
    6. McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 2016 Sep 26. PMID: 27669432.
      View in: PubMed
    7. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016 Sep 26; 7:12791. PMID: 27666543.
      View in: PubMed
    8. Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY. Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. Semin Radiat Oncol. 2017 Jan; 27(1):11-20. PMID: 27986207.
      View in: PubMed
    9. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 Dec 1; 96(5):1046-1053. PMID: 27745980.
      View in: PubMed
    10. Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng FY, Boutros PC, Freedman ML, Walsh MJ, He HH. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016 Oct; 48(10):1142-50. PMID: 27526323.
      View in: PubMed
    11. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4):770-777. PMID: 27663760.
      View in: PubMed
    12. Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016 Aug 1; 126(8):2775-82. PMID: 27479746.
      View in: PubMed
    13. Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016 Aug 1; 2(8):1070-4. PMID: 27366979.
      View in: PubMed
    14. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. PMID: 27434225.
      View in: PubMed
    15. Jackson WC, Schipper MJ, Feng FY. Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Eur Urol. 2016 Dec; 70(6):e159. PMID: 27210457.
      View in: PubMed
    16. Malik B, Feng FY. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J Androl. 2016 Jul-Aug; 18(4):568-74. PMID: 27072044.
      View in: PubMed
    17. Li YL, Feng F, Yan J, Chen LL, Li XL, Liu WH, Yang YF. [Association between cured meat consumption and risk of colorectal cancer in people with different dietary habits and lifestyles]. Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Jul; 37(7):1006-11. PMID: 27453114.
      View in: PubMed
    18. Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. 2016 Oct; 13(10):597-610. PMID: 27245282.
      View in: PubMed
    19. Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY. Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016 Sep; 19(3):292-7. PMID: 27215611.
      View in: PubMed
    20. Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016 Sep; 27(9):1706-12. PMID: 27217541.
      View in: PubMed
    21. Sapir E, Tao Y, Feng F, Samuels S, El Naqa I, Murdoch-Kinch CA, Feng M, Schipper M, Eisbruch A. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96(2):354-61. PMID: 27473816.
      View in: PubMed
    22. Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis. 2016 Sep; 19(3):277-82. PMID: 27136742.
      View in: PubMed
    23. Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 Sep; 34(9):415.e1-6. PMID: 27140065.
      View in: PubMed
    24. Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016 Nov; 118(5):763-769. PMID: 27009882.
      View in: PubMed
    25. Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia. 2016 Apr; 18(4):213-22. PMID: 27108384.
      View in: PubMed
    26. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 Apr; 14(4):421-8. PMID: 27059190.
      View in: PubMed
    27. Vainshtein JM, Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):173-80. PMID: 24487421.
      View in: PubMed
    28. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr 1; 2(4):471-80. PMID: 26746117.
      View in: PubMed
    29. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 May 15; 122(10):1505-12. PMID: 26970022.
      View in: PubMed
    30. Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy. Prostate Cancer Prostatic Dis. 2016 Jun; 19(2):216-21. PMID: 26951715.
      View in: PubMed
    31. Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6. PMID: 26985191.
      View in: PubMed
    32. Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. Mol Biol Rep. 2016 Apr; 43(4):229-40. PMID: 26907180.
      View in: PubMed
    33. Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol. 2016 Aug; 196(2):405-11. PMID: 26920466.
      View in: PubMed
    34. Zhao F, Bi L, Wang W, Wu X, Li Y, Gong F, Lu S, Feng F, Qian Z, Hu C, Wu Y, Sun Y. Mutations of glucocerebrosidase gene and susceptibility to Parkinson's disease: An updated meta-analysis in a European population. Neuroscience. 2016 Apr 21; 320:239-46. PMID: 26868973.
      View in: PubMed
    35. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. 2016 Oct; 70(4):588-596. PMID: 26806658.
      View in: PubMed
    36. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res. 2016 Apr; 14(4):324-31. PMID: 26792867.
      View in: PubMed
    37. Feng FY, Kothari V. Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer. Proc Natl Acad Sci U S A. 2016 Jan 19; 113(3):473-5. PMID: 26747602.
      View in: PubMed
    38. Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia. 2016 Jan; 18(1):1-9. PMID: 26806347.
      View in: PubMed
    39. Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol. 2015 Dec 23. PMID: 26724257.
      View in: PubMed
    40. McDaniel AS, Hovelson DH, Cani AK, Liu CJ, Zhai Y, Zhang Y, Weizer AZ, Mehra R, Feng FY, Alva AS, Morgan TM, Montgomery JS, Siddiqui J, Sadis S, Bandla S, Williams PD, Cho KR, Rhodes DR, Tomlins SA. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. Cancer Res. 2015 Dec 15; 75(24):5219-27. PMID: 26670561.
      View in: PubMed
    41. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. PMID: 26972640.
      View in: PubMed
    42. Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res. 2016 Apr 1; 22(7):1777-86. PMID: 26631616.
      View in: PubMed
    43. Zhao SG, Alexander NB, Djuric Z, Zhou J, Tao Y, Schipper M, Feng FY, Eisbruch A, Worden FP, Strath SJ, Jolly S. Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head Neck. 2016 Apr; 38 Suppl 1:E1086-96. PMID: 26445898.
      View in: PubMed
    44. Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249. PMID: 26442515.
      View in: PubMed
    45. Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA. Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol. 2015 Oct; 38(5):465-71. PMID: 24064749.
      View in: PubMed
    46. Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. PMID: 26235660.
      View in: PubMed
    47. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101. PMID: 26207642.
      View in: PubMed
    48. Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84. PMID: 26276528.
      View in: PubMed
    49. Jackson WC, Johnson SB, Feng FY, Hamstra DA. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015 Aug; 38(4):367-72. PMID: 23822986.
      View in: PubMed
    50. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35. PMID: 26530751.
      View in: PubMed
    51. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 2015 Jul 13; 28(1):97-113. PMID: 26175416; PMCID: PMC4531387 [Available on 07/13/16].
    52. Nguyen PL, Shin H, Yousefi K, Thompson DJ, Hornberger J, Hyatt AS, Badani KK, Morgan TM, Feng FY. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology. 2015 Jul; 86(1):35-40. PMID: 26142578.
      View in: PubMed
    53. Feng FY, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell. 2015 Jun 18; 58(6):925-34. PMID: 26091341; PMCID: PMC4487541 [Available on 06/18/16].
    54. Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. Neoplasia. 2015 Jun; 17(6):490-6. PMID: 26152357.
      View in: PubMed
    55. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2016 Jan; 69(1):50-7. PMID: 26004800.
      View in: PubMed
    56. Zhao SG, Shilkrut M, Speers C, Liu M, Wilder-Romans K, Lawrence TS, Pierce LJ, Feng FY. Development and validation of a novel platform-independent metastasis signature in human breast cancer. PLoS One. 2015; 10(5):e0126631. PMID: 25974184; PMCID: PMC4431866.
    57. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol. 2015 Oct; 68(4):555-67. PMID: 25964175; PMCID: PMC4562381 [Available on 10/01/16].
    58. Liss AL, Abu-Isa EI, Jawad MS, Feng FY, Vance SM, Winfield RJ, Narayana V, Sandler HM, McLaughlin PW, Hamstra DA. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. Brachytherapy. 2015 Jul-Aug; 14(4):502-10. PMID: 25911994.
      View in: PubMed
    59. Speers C, Zhao S, Liu M, Bartelink H, Pierce LJ, Feng FY. Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. Clin Cancer Res. 2015 Aug 15; 21(16):3667-77. PMID: 25904749.
      View in: PubMed
    60. Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng FY, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015 Apr; 17(4):385-99. PMID: 25925381; PMCID: PMC4415141.
    61. Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2015 Apr 1; 91(5):925-33. PMID: 25832685; PMCID: PMC4384167 [Available on 04/01/16].
    62. Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015 Apr; 21(4):344-52. PMID: 25822367; PMCID: PMC4390530.
    63. Augello MA, Berman-Booty LD, Carr R, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE. Consequence of the tumor-associated conversion to cyclin D1b. EMBO Mol Med. 2015 May; 7(5):628-47. PMID: 25787974; PMCID: PMC4492821.
    64. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015 Mar; 47(3):199-208. PMID: 25599403; PMCID: PMC4417758.
    65. Warrick JI, Hovelson DH, Amin A, Liu CJ, Cani AK, McDaniel AS, Yadati V, Quist MJ, Weizer AZ, Brenner JC, Feng FY, Mehra R, Grasso CS, Tomlins SA. Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. Virchows Arch. 2015 Mar; 466(3):297-311. PMID: 25502898.
      View in: PubMed
    66. Morgan TM, Feng FY. Editorial comment. Urology. 2014 Dec; 84(6):1432-3. PMID: 25432833.
      View in: PubMed
    67. Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, Feng FY, Chinnaiyan AM. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia. 2014 Dec; 16(12):1121-7. PMID: 25499224; PMCID: PMC4309259.
    68. Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol. 2014; 9:245. PMID: 25424123; PMCID: PMC4255426.
    69. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng FY. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014 Nov; 16(11):900-8. PMID: 25425964; PMCID: PMC4240923.
    70. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014 Dec; 15(13):1469-80. PMID: 25456366; PMCID: PMC4559342 [Available on 12/01/15].
    71. Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 2014 Oct; 7(5):644-9. PMID: 25389460; PMCID: PMC4225651.
    72. Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. Clin Cancer Res. 2014 Dec 15; 20(24):6379-88. PMID: 25294917; PMCID: PMC4299458 [Available on 12/15/15].
    73. Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ. Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer. Breast Cancer Res Treat. 2014 Aug; 147(1):81-94. PMID: 25104443.
      View in: PubMed
    74. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY, Chinnaiyan AM. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res. 2014 Aug; 12(8):1081-7. PMID: 25030374; PMCID: PMC4135019.
    75. Popovtzer A, Ibrahim M, Tatro D, Feng FY, Ten Haken RK, Eisbruch A. MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used? Radiol Oncol. 2014 Sep; 48(3):323-30. PMID: 25177248; PMCID: PMC4110090.
    76. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Aug 1; 89(5):1038-46. PMID: 25035207; PMCID: PMC4432840.
    77. Feng FY, Brenner JC, Hussain M, Chinnaiyan AM. Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res. 2014 Sep 1; 20(17):4442-8. PMID: 24958807; PMCID: PMC4155001.
    78. Kozminski MA, Palapattu GS, Mehra R, Montgomery JS, Weizer AZ, Skolarus TA, Hollenbeck BK, Miller DC, He C, Tomlins S, Montie JE, Feng FY, Wood DP, Kunju LP, Morgan TM. Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. Urology. 2014 Aug; 84(2):373-8. PMID: 24958484.
      View in: PubMed
    79. Zhao S, Chang SL, Linderman JJ, Feng FY, Luker GD. A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer(1,2.) Transl Oncol. 2014 May 13. PMID: 24836649.
      View in: PubMed
    80. Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2014 Aug 1; 89(5):973-80. PMID: 24803039.
      View in: PubMed
    81. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014 Jun 12; 510(7504):278-82. PMID: 24759320; PMCID: PMC4075966.
    82. Li MY, Zhu M, Feng F, Cai FY, Fan KC, Jiang H, Wang ZQ, Linghu EQ. Long interspersed nucleotide acid element-1 ORF-1 protein promotes proliferation and invasion of human colorectal cancer LoVo cells through enhancing ETS-1 activity. Genet Mol Res. 2014; 13(3):6981-94. PMID: 24782214.
      View in: PubMed
    83. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014 Mar 30; 5(6):1434-8. PMID: 24727738; PMCID: PMC4039221.
    84. Johnson S, Jackson W, Speers C, Feng F, Hamstra D. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):422-9. PMID: 25407865.
      View in: PubMed
    85. Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, Worden FP, Wolf GT, Chepeha DB, Prince ME, Bradford CR, Mukherji SK, Eisbruch A, Carey TE. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014 Mar 1; 88(3):580-8. PMID: 24521676; PMCID: PMC3989890.
    86. Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol. 2014 Feb; 110(2):291-7. PMID: 24507766.
      View in: PubMed
    87. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60. PMID: 24473064; PMCID: PMC4009928.
    88. Cao Q, Wang X, Zhao M, Yang R, Malik R, Qiao Y, Poliakov A, Yocum AK, Li Y, Chen W, Cao X, Jiang X, Dahiya A, Harris C, Feng FY, Kalantry S, Qin ZS, Dhanasekaran SM, Chinnaiyan AM. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014; 5:3127. PMID: 24457600; PMCID: PMC4073494.
    89. Farjam R, Tsien CI, Feng FY, Gomez-Hassan D, Hayman JA, Lawrence TS, Cao Y. Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy. Neuro Oncol. 2014 Jan; 16(1):131-9. PMID: 24327584; PMCID: PMC3870818.
    90. Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry. Head Neck. 2014 Sep; 36(9):1356-62. PMID: 23970480.
      View in: PubMed
    91. Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):64-9. PMID: 24145624; PMCID: PMC4332821.
    92. Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia. 2013 Oct; 15(10):1207-17. PMID: 24204199; PMCID: PMC3819636.
    93. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013 Nov; 45(11):1392-8. PMID: 24076601; PMCID: PMC3812362.
    94. Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013 Nov; 3(11):1254-71. PMID: 24027197; PMCID: PMC3823813.
    95. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 1; 87(2):275-81. PMID: 23886418.
      View in: PubMed
    96. Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):99-107. PMID: 24890350.
      View in: PubMed
    97. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol. 2013; 8:170. PMID: 23835115; PMCID: PMC3718717.
    98. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer. 2013 Sep 15; 119(18):3287-94. PMID: 23821578.
      View in: PubMed
    99. Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos T, Chepeha DB, Walline HM, McHugh JB, Cordell KG, Ward PD, Byrd S, Maxwell JH, Urba S, Bradford CR, Carey TE, Worden FP. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. Head Neck. 2014 May; 36(5):617-23. PMID: 23596055; PMCID: PMC4205960.
    100. Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head Neck. 2014 Jan; 36(1):120-5. PMID: 23729173; PMCID: PMC4144677.
    101. Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):721-8. PMID: 23664325.
      View in: PubMed
    102. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013 Jun; 3(6):636-47. PMID: 23558953; PMCID: PMC3694764.
    103. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 1; 86(3):554-61. PMID: 23561650.
      View in: PubMed
    104. White NM, Feng FY, Maher CA. Recurrent rearrangements in prostate cancer: causes and therapeutic potential. Curr Drug Targets. 2013 Apr; 14(4):450-9. PMID: 23410129; PMCID: PMC3733264.
    105. Farjam R, Tsien CI, Feng FY, Hayman JA, Lawrence TS, Cao Y. Diffusion abnormality index: a new imaging biomarker for early assessment of tumor response to therapy. Pract Radiat Oncol. 2013 Apr-Jun; 3(2 Suppl 1):S5. PMID: 24674561.
      View in: PubMed
    106. Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013 May 1; 86(1):64-71. PMID: 23462420.
      View in: PubMed
    107. Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2013 Jan; 123(1):493-508. PMID: 23257359; PMCID: PMC3533295.
    108. Zeng YH, Koblížek M, Li YX, Liu YP, Feng FY, Ji JD, Jian JC, Wu ZH. Long PCR-RFLP of 16S-ITS-23S rRNA genes: a high-resolution molecular tool for bacterial genotyping. J Appl Microbiol. 2013 Feb; 114(2):433-47. PMID: 23126629.
      View in: PubMed
    109. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85(5):1246-53. PMID: 23265567.
      View in: PubMed
    110. Farjam R, Tsien CI, Feng FY, Gomez-Hassan D, Hayman JA, Lawrence TS, Cao Y. Physiological imaging-defined, response-driven subvolumes of a tumor. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85(5):1383-90. PMID: 23257692; PMCID: PMC3638951.
    111. Grivas PD, Davenport M, Montie JE, Kunju LP, Feng F, Weizer AZ. Urethral cancer. Hematol Oncol Clin North Am. 2012 Dec; 26(6):1291-314. PMID: 23116581.
      View in: PubMed
    112. Chang SS, Dinney CP, Donat SM, Dahm P, Gore JL, Lotan Y, Parekh DJ, Solit DB, O'Donnell PH, Feng FY, Hansel D, Milowsky MI. 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urol Oncol. 2012 Nov-Dec; 30(6):944-7. PMID: 23218073.
      View in: PubMed
    113. Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CS, Chepeha DB, Eisbruch A. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):935-40. PMID: 23040224; PMCID: PMC3556374.
    114. Shilkrut M, Feng F, Hamstra DA. General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V. Front Oncol. 2012; 2:126. PMID: 23061043; PMCID: PMC3459002.
    115. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng F, Knudsen KE. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012 Dec; 2(12):1134-49. PMID: 22993403; PMCID: PMC3519969.
    116. Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 2013 Feb 1; 119(3):681-90. PMID: 22893254.
      View in: PubMed
    117. Murgic J, Stenmark MH, Halverson S, Blas K, Feng FY, Hamstra DA. The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. Radiat Oncol. 2012; 7:127. PMID: 22852797; PMCID: PMC3484035.
    118. Sabolch A, Feng M, Griffith K, Rzasa C, Gadzala L, Feng F, Biermann JS, Chugh R, Ray M, Ben-Josef E. Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity. Am J Clin Oncol. 2012 Apr; 35(2):151-7. PMID: 21336091.
      View in: PubMed
    119. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012 Apr 1; 72(7):1608-13. PMID: 22287547; PMCID: PMC3319786.
    120. Pak D, Vineberg K, Feng F, Ten Haken RK, Eisbruch A. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. Int J Radiat Oncol Biol Phys. 2012 Aug 1; 83(5):1528-33. PMID: 22284690; PMCID: PMC3481166.
    121. Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):921-6. PMID: 22208966.
      View in: PubMed
    122. Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch CA, Eisbruch A. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):1007-14. PMID: 22056067; PMCID: PMC3288420.
    123. Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):940-6. PMID: 22056069.
      View in: PubMed
    124. Tong L, Yuan S, Feng F, Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus. 2012 Jan; 25(1):72-80. PMID: 21895849.
      View in: PubMed
    125. Kapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA. Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer. 2012 Apr 15; 118(8):2059-68. PMID: 22009287.
      View in: PubMed
    126. Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e361-7. PMID: 21820250.
      View in: PubMed
    127. Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol. 2011 Dec; 101(3):513-20. PMID: 21703711.
      View in: PubMed
    128. Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e335-44. PMID: 21645976.
      View in: PubMed
    129. Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys. 2011 Nov 1; 81(3):e93-9. PMID: 21592678; PMCID: PMC3158965.
    130. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011 May 17; 19(5):664-78. PMID: 21575865; PMCID: PMC3113473.
    131. Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e351-60. PMID: 21493015.
      View in: PubMed
    132. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med. 2011 Mar 2; 3(72):72ra17. PMID: 21368222; PMCID: PMC3211047.
    133. Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1; 81(3):e135-42. PMID: 21345617.
      View in: PubMed
    134. Feng F, Xiang Y, Wan X, Geng S, Wang T. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. Ann Oncol. 2011 Jul; 22(7):1588-94. PMID: 21239399.
      View in: PubMed
    135. Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011 Jul 1; 80(3):787-92. PMID: 20615622.
      View in: PubMed
    136. Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A, Worden FP, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, Stoerker J, Walline H, Carey TE, Bradford CR. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck. 2010 May; 32(5):562-7. PMID: 19757421; PMCID: PMC2855405.
    137. Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010 Jun 1; 28(16):2732-8. PMID: 20421546; PMCID: PMC2881852.
    138. Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, Eisbruch A. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76(3 Suppl):S64-9. PMID: 20171520; PMCID: PMC2833104.
    139. Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, Bradford CR, Carey TE. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010 Feb 15; 16(4):1226-35. PMID: 20145161; PMCID: PMC2822887.
    140. Feng F, Akiyama K, Liu Y, Yamaza T, Wang TM, Chen JH, Wang BB, Huang GT, Wang S, Shi S. Utility of PDL progenitors for in vivo tissue regeneration: a report of 3 cases. Oral Dis. 2010 Jan; 16(1):20-8. PMID: 20355278; PMCID: PMC2848819.
    141. Yang J, Li M, Zhang H, Hong L, Feng F, Pan F, Wang Y, Wang W. Application of a self-made swivel intravenous transfusion device in constructing allogenic small bowel transplantation rejection model in rats. Transplant Proc. 2009 Dec; 41(10):4397-400. PMID: 20005407.
      View in: PubMed
    142. Zhu ZY, Wang CM, Lo LC, Lin G, Feng F, Tan J, Chou R, Lim HS, Orban L, Yue GH. A standard panel of microsatellites for Asian seabass (Lates calcarifer). Anim Genet. 2010 Apr; 41(2):208-12. PMID: 19793264.
      View in: PubMed
    143. Gluck I, Feng FY, Lyden T, Haxer M, Worden F, Chepeha DB, Eisbruch A. Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 1; 77(3):727-33. PMID: 19783380; PMCID: PMC2878868.
    144. Popovtzer A, Cao Y, Feng FY, Eisbruch A. Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose-effect relationships: MRI-based study. Radiother Oncol. 2009 Dec; 93(3):510-5. PMID: 19520446; PMCID: PMC2787803.
    145. Zhu ZY, Wang CM, Feng F, Yue GH. Isolation and characterization of 51 microsatellites from BAC clones in Asian seabass, Lates calcarifer. Anim Genet. 2009 Feb; 40(1):125-6. PMID: 18945291.
      View in: PubMed
    146. Feng FY, Ben-Josef E. Radiation therapy improves survival in patients with pancreatic adenocarcinoma. Nat Clin Pract Oncol. 2008 Aug; 5(8):434-5. PMID: 18594497.
      View in: PubMed
    147. Zhang H, Lu Z, Wang S, Shen Y, Feng F, Zheng X. Development and antifungal evaluation of a food-grade U-type microemulsion. J Appl Microbiol. 2008 Oct; 105(4):993-1001. PMID: 18422551.
      View in: PubMed
    148. Wang CM, Lo LC, Feng F, Zhu ZY, Yue GH. Identification and verification of QTL associated with growth traits in two genetic backgrounds of Barramundi (Lates calcarifer). Anim Genet. 2008 Feb; 39(1):34-9. PMID: 18076743.
      View in: PubMed
    149. Wang G, Jacobson JA, Feng FY, Girish G, Caoili EM, Brandon C. Sonography of wrist ganglion cysts: variable and noncystic appearances. J Ultrasound Med. 2007 Oct; 26(10):1323-8; quiz 1330-1. PMID: 17901135.
      View in: PubMed
    150. Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys. 2007 Sep 1; 69(1):214-20. PMID: 17707275.
      View in: PubMed
    151. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007 Aug 1; 68(5):1289-98. PMID: 17560051.
      View in: PubMed
    152. Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence TS, Nyati MK. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res. 2007 Apr 15; 13(8):2512-8. PMID: 17438112.
      View in: PubMed
    153. Eisbruch A, Levendag PC, Feng FY, Teguh D, Lyden T, Schmitz PI, Haxer M, Noever I, Chepeha DB, Heijmen BJ. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S40-2. PMID: 17848291; PMCID: PMC2801073.
    154. Nyati MK, Feng FY, Maheshwari D, Varambally S, Zielske SP, Ahsan A, Chun PY, Arora VA, Davis MA, Jung M, Ljungman M, Canman CE, Chinnaiyan AM, Lawrence TS. Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. Cancer Res. 2006 Dec 15; 66(24):11554-9. PMID: 17178844.
      View in: PubMed
    155. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, Nyati MK. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007 May 17; 26(23):3431-9. PMID: 17146438.
      View in: PubMed
    156. Carr JM, Davis AJ, Feng F, Burrell CJ, Li P. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more? Curr Drug Targets. 2006 Dec; 7(12):1583-93. PMID: 17168833.
      View in: PubMed
    157. Xu JM, Song ST, Feng FY, Huang FL, Yang Y, Xie GR, Xu LG, Zhang CZ, Bruno M, Paradiso A. Cobrotoxin-containing analgesic compound to treat chronic moderate to severe cancer pain: results from a randomized, double-blind, cross-over study and from an open-label study. Oncol Rep. 2006 Nov; 16(5):1077-84. PMID: 17016596.
      View in: PubMed
    158. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006 Nov; 6(11):876-85. PMID: 17036041.
      View in: PubMed
    159. Zhu ZY, Wang CM, Lo LC, Feng F, Lin G, Yue GH. Isolation, characterization, and linkage analyses of 74 novel microsatellites in Barramundi (Lates calcarifer). Genome. 2006 Aug; 49(8):969-76. PMID: 17036072.
      View in: PubMed
    160. Nyati MK, Feng FY, Kanade VD, Nayak R. Chloroquine treatment increases detection of 5-fluorouracil-induced apoptosis index in vivo. Mol Imaging. 2006 Jul; 5(3):148-52. PMID: 16954029.
      View in: PubMed
    161. Xu YX, Zhu ZY, Lo LC, Wang CM, Lin G, Feng F, Yue GH. Characterization of two parvalbumin genes and their association with growth traits in Asian seabass (Lates calcarifer). Anim Genet. 2006 Jun; 37(3):266-8. PMID: 16734689.
      View in: PubMed
    162. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res. 2006 Jan 15; 66(2):981-8. PMID: 16424033.
      View in: PubMed
    163. Lin G, Lo LC, Zhu ZY, Feng F, Chou R, Yue GH. The complete mitochondrial genome sequence and characterization of single-nucleotide polymorphisms in the control region of the Asian seabass (Lates calcarifer). Mar Biotechnol (NY). 2006 Jan-Feb; 8(1):71-9. PMID: 16228120; PMCID: PMC4273291.
    164. Matei V, Pauley S, Kaing S, Rowitch D, Beisel KW, Morris K, Feng F, Jones K, Lee J, Fritzsch B. Smaller inner ear sensory epithelia in Neurog 1 null mice are related to earlier hair cell cycle exit. Dev Dyn. 2005 Nov; 234(3):633-50. PMID: 16145671; PMCID: PMC1343505.
    165. Huang Z, Zhou W, Zhou C, Han S, Zhang A, Feng F, Liu C, Wang L. Determination of semivolatile compounds in drinking water by tandem mass spectrometric detection. Bull Environ Contam Toxicol. 2003 Nov; 71(5):1026-33. PMID: 14705665.
      View in: PubMed
    166. Peng X, Feng F, Zhang W. [Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense]. Zhonghua Zhong Liu Za Zhi. 2001 Sep; 23(5):355-8. PMID: 11810759.
      View in: PubMed
    167. Feng F, He X, Shi Y. [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]. Zhonghua Zhong Liu Za Zhi. 2001 Mar; 23(2):155-8. PMID: 11783024.
      View in: PubMed
    168. Feng FY, Ogden MA, Myckatyn TM, Grand AG, Jensen JN, Hunter DA, Mackinnon SE. FK506 rescues peripheral nerve allografts in acute rejection. J Neurotrauma. 2001 Feb; 18(2):217-29. PMID: 11229713.
      View in: PubMed
    169. Zhou A, Feng F, Shi Y. [Clinical analysis of 10 cases of true histiocytic lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2000 Nov; 21(11):584-6. PMID: 11225249.
      View in: PubMed
    170. Feng F, Rittling SR. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat. 2000 Sep; 63(1):71-9. PMID: 11079161.
      View in: PubMed
    171. Ogden MA, Feng FY, Myckatyn TM, Jensen JN, Grand AG, Wood PW, Hunter DA, MacKinnon SE. Safe injection of cultured schwann cells into peripheral nerve allografts. Microsurgery. 2000; 20(7):314-23. PMID: 11119286.
      View in: PubMed
    172. Peng X, Feng F, Zhang W. [Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in human rectal carcinomas and its clinical significance]. Zhonghua Zhong Liu Za Zhi. 1999 May; 21(3):193-5. PMID: 11776833.
      View in: PubMed
    173. Zhang X, Sun Y, Feng F. [Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases]. Zhonghua Zhong Liu Za Zhi. 1999 May; 21(3):220-3. PMID: 11776842.
      View in: PubMed
    174. Zou Y, Shen Y, Shu L, Wang Y, Feng F, Xu K, Ou Y, Song Y, Zhong Y, Wang M, Liu W. Artificial neural network to assist psychiatric diagnosis. Br J Psychiatry. 1996 Jul; 169(1):64-7. PMID: 8818370.
      View in: PubMed
    175. Feng F, Zhou L, Mang Z, Liu H, Sun Y. [Phase I clinical study of a new anticancer drug boanmycin]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1996 Apr; 18(2):143-6. PMID: 9208606.
      View in: PubMed
    176. Zhang P, Zhou J, Feng F. [The clinical efficacy of CAC regimen in the treatment of advanced breast cancer]. Zhonghua Zhong Liu Za Zhi. 1995 Sep; 17(5):365-7. PMID: 8697977.
      View in: PubMed
    177. Luo KH, Shi YK, Sun Y, Wang QL, Wu GQ, Feng FY, Cui W, Liu HB. A practical procedure for the cryopreservation of marrow cells intended for autotransplantation. Leuk Lymphoma. 1995 May; 17(5-6):495-9. PMID: 7549843.
      View in: PubMed
    178. Shi YK, Feng FY, Sun Y. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients]. Zhonghua Nei Ke Za Zhi. 1994 Nov; 33(11):739-42. PMID: 7541325.
      View in: PubMed
    179. Shi YK, Zhou JC, Feng FY. [Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients]. Zhonghua Zhong Liu Za Zhi. 1994 May; 16(3):207-10. PMID: 7525173.
      View in: PubMed
    180. Feng F, Abel PW, Scofield M, Liu F, Wolff DW, Jeffries WB. Heterogeneous expression of alpha 1-adrenoceptor subtypes among rat nephron segments. Mol Pharmacol. 1993 Nov; 44(5):926-33. PMID: 8246915.
      View in: PubMed
    181. Wang QL, Sun Y, Zhou JC, Song SZ, Feng FY, Lu L, Yie ZS. [High-dose methotrexate with citrovorum factor rescue (HD-MTX-CFR) in the treatment of malignant solid tumors--clinical analysis of 62 patients]. Zhonghua Zhong Liu Za Zhi. 1988 Mar; 10(2):152-4. PMID: 3264785.
      View in: PubMed
    182. Sun Y, Yin WB, Feng FY, Wang JW, Qiu Q, Wang QL, Bai L, Zhou JC, Song SZ. [COMVp regimen in the treatment of small cell lung cancer--report of 106 patients]. Zhonghua Zhong Liu Za Zhi. 1987 Jul; 9(4):302-4. PMID: 2824152.
      View in: PubMed
    183. Zhou JC, Feng FY, Sun Y, Wang QL, Zeng WY, Liu YY. [Evaluation of combined chemotherapy including high-dose cisplatin in the treatment of malignant tumors]. Zhonghua Zhong Liu Za Zhi. 1987 Mar; 9(2):136-9. PMID: 2820683.
      View in: PubMed
    Felix's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP